GRIFOLS overview

LOS ANGELES, CA / ACCESSWIRE / May 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain, April 19, 2024 BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023 , with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report on...

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the world An engineering masterwork, the Clayton site is a model for new Grifols...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, March 27, 2024 NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, March 19, 2024 NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...